The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2025 | TaZa CLL: tafasitamab and zanubrutinib in newly diagnosed CLL
Georgios Pongas, MD, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, discusses the results of the ongoing TaZa CLL study (NCT05718869), an investigator-initiated Phase II trial investigating tafasitamab and zanubrutinib in newly diagnosed patients with chronic lymphocytic leukemia (CLL). Dr Pongas highlights the combination’s ability to achieve high overall response rates (ORR) and progression-free survival (PFS), noting that the treatment is well-tolerated. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
